143 related articles for article (PubMed ID: 35635904)
1. Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses.
Jia L; Wang L; Jiang Y; Xu L; Cai Y; Chen Y; Jin J; Sun H; Zhu J
Comput Biol Med; 2022 Aug; 147():105642. PubMed ID: 35635904
[TBL] [Abstract][Full Text] [Related]
2. Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening.
Zhu J; Sun D; Li X; Jia L; Cai Y; Chen Y; Jin J; Yu L
Comput Biol Chem; 2023 Jun; 104():107879. PubMed ID: 37182359
[TBL] [Abstract][Full Text] [Related]
3. Rational Design of Novel Phosphoinositide 3-Kinase Gamma (PI3Kγ) Selective Inhibitors: A Computational Investigation Integrating 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Li K; Zhu J; Xu L; Jin J
Chem Biodivers; 2019 Jul; 16(7):e1900105. PubMed ID: 31111650
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation.
Zhu J; Li K; Xu L; Cai Y; Chen Y; Zhao X; Li H; Huang G; Jin J
J Adv Res; 2022 Feb; 36():1-13. PubMed ID: 35127160
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
6. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
7. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
8. Insight into the selective mechanism of phosphoinositide 3-kinase γ with benzothiazole and thiazolopiperidine γ-specific inhibitors by in silico approaches.
Zhu J; Li K; Xu L; Jin J
Chem Biol Drug Des; 2019 May; 93(5):818-831. PubMed ID: 30582283
[TBL] [Abstract][Full Text] [Related]
9. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
Sabbah DA; Vennerstrom JL; Zhong HA
J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
11. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
12. Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors.
Tanneeru K; Guruprasad L
J Mol Model; 2012 Apr; 18(4):1611-24. PubMed ID: 21805127
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Phosphatidylinositol 3-Kinase γ by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice.
Liu R; Huang J; Ge Y; Liu S; Huang T; Cai H; Pan B; Zhang Q; Yang P; Liao M; Xu B; Wang W
Eur J Vasc Endovasc Surg; 2020 Aug; 60(2):254-263. PubMed ID: 32423743
[TBL] [Abstract][Full Text] [Related]
14. Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric Carcinoma.
Ghosh S; Cho SJ
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453562
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist.
Liang Y; Zheng Y; Yang J; Ke J; Cheng K
Bioorg Med Chem; 2023 Apr; 84():117261. PubMed ID: 37011446
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia.
Faehling S; Coelho M; Floerchinger A; Schneider C; Stilgenbauer S; Lichter P; Seiffert M; Roessner PM
Hemasphere; 2023 Mar; 7(3):e840. PubMed ID: 36844182
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
[TBL] [Abstract][Full Text] [Related]
18. Developing a Naïve Bayesian Classification Model with PI3Kγ structural features for virtual screening against PI3Kγ: Combining molecular docking and pharmacophore based on multiple PI3Kγ conformations.
Jiang Y; Xiong W; Jia L; Xu L; Cai Y; Chen Y; Jin J; Gao M; Zhu J
Eur J Med Chem; 2022 Dec; 244():114824. PubMed ID: 36257282
[TBL] [Abstract][Full Text] [Related]
19. Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors.
Al Hasan M; Sabirianov M; Redwine G; Goettsch K; Yang SX; Zhong HA
J Mol Graph Model; 2023 Jun; 121():108433. PubMed ID: 36812742
[TBL] [Abstract][Full Text] [Related]
20. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors.
Zhu J; Li K; Yu L; Chen Y; Cai Y; Jin J; Hou T
Med Res Rev; 2021 May; 41(3):1599-1621. PubMed ID: 33300614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]